2 results
Approved WMORecruiting
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.
Approved WMOCompleted
Primary objectiveTo compare the event free survival per pathological review committee (PRC) of nivolumab plus BCG vs BCG alone in all randomized ParticipantsEFS, defined as the time from randomization until any of the following events: recurrence (…